JMJD

亜型選択性的な製品

JMJD製品

  • All (9)
  • JMJD阻害剤 (9)
  • 新製品
製品コード 製品名称 製品説明 文献中Selleckの製品使用例 お客様のフィードバック
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
J Clin Invest, 2024, 134(1)e163964
Acta Pharm Sin B, 2023, 13(6):2601-2612
Nat Immunol, 2022, 23(3):431-445
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Cancer Cell, 2023, 41(6):1118-1133.e12
mBio, 2022, 13(1):e0337721
iScience, 2022, 25(9):104978
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
Viruses, 2023, 15(1)163
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Nat Commun, 2023, 14(1):1161
Nat Commun, 2022, 13(1):1172
Chem Biol Drug Des, 2022, 10.1111/cbdd.14051
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Cell Rep Med, 2023, 4(5):101026
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
J Biol Chem, 2022, S0021-9258(22)00457-4
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
Exp Cell Res, 2021, S0014-4827(21)00315-3
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.
S7070 GSK J4 HCl GSK J4 HCl is a cell permeable prodrug of GSK J1, which is the first selective inhibitor of the H3K27 histone demethylase JMJD3 and UTX with IC50 of 60 nM in a cell-free assay and inactive against a panel of demethylases of the JMJ family.
J Clin Invest, 2024, 134(1)e163964
Acta Pharm Sin B, 2023, 13(6):2601-2612
Nat Immunol, 2022, 23(3):431-445
S8287 CPI-455 HCl CPI-455 HCl is a specific KDM5 inhibitor, elevating global levels of H3K4 trimethylation (H3K4me3) and decreased the number of DTPs in multiple cancer cell line models treated with standard chemotherapy or targeted agents.
Nature, 2023, 622(7983):619-626
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
S7281 JIB-04 JIB-04 (NSC 693627) is a pan-selective Jumonji histone demethylase inhibitor with IC50 of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D in cell-free assays, respectively. JIB‑04 also induces cell apoptosis.
Cancer Cell, 2023, 41(6):1118-1133.e12
mBio, 2022, 13(1):e0337721
iScience, 2022, 25(9):104978
S7296 ML324 ML324 is a selective inhibitor of jumonji histone demethylase (JMJD2) with IC50 of 920 nM.
Cancer Cell, 2023, 41(6):1118-1133.e12
EBioMedicine, 2023, 92:104602
Viruses, 2023, 15(1)163
S7234 IOX1 IOX1 is a potent and broad-spectrum inhibitor of 2OG oxygenases, including the JmjC demethylases. IOX1 is an inhibitor of ALKBH5.
Nat Commun, 2023, 14(1):1161
Nat Commun, 2022, 13(1):1172
Chem Biol Drug Des, 2022, 10.1111/cbdd.14051
S7581 GSK J1 GSK-J1 is a highly potent H3K27 histone demethylase inhibitor with IC50 of 28 nM and 53 nM in cell-free assays for JMJD3 (KDM6B) and UTX (KDM6A), respectively, >10-fold selectivity over other tested demethylases.
Cell Rep Med, 2023, 4(5):101026
Nat Chem Biol, 2022, 10.1038/s41589-022-00996-7
J Biol Chem, 2022, S0021-9258(22)00457-4
S8601 CP2 CP2 is a cyclic peptide that inhibits the JmjC histone demethylases KDM4 with IC50 values of 42 nM and 29 nM for KDM4A and KDM4C, respectively.
Oxid Med Cell Longev, 2022, 2022:2405943
Front Cell Dev Biol, 2021, 9:697614
Exp Cell Res, 2021, S0014-4827(21)00315-3
E1315 iJMJD6 iJMJD6(WL12) is an inhibitor of arginine demethylase JMJD6 with an IC50 value of 0.22 μM.
S0201 Z-JIB-04 (NSC 693627) Z-JIB-04 (NSC 693627, JIB-04 Z-isomer) is an isomer of JIB-04. JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC50 of 230 nM, 340 nM, 855 nM, 445 nM, 435 nM, 1100 nM and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

JMJD阻害剤の選択性比較

Tags: JMJD inhibitor | JMJD modulator | JMJD chemical